A. Shah

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

G. Curigliano, M. Fakih, M. Overman, 2022, Journal for ImmunoTherapy of Cancer.

Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.

M. Fakih, M. Overman, S. Lonardi, 2022, European journal of cancer.

Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).

A. Bardelli, R. Yaeger, S. Kopetz, 2021 .

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer

M. Fakih, R. Miceli, M. Overman, 2023, Journal for ImmunoTherapy of Cancer.

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

G. Curigliano, M. Fakih, R. Miceli, 2021, Journal for ImmunoTherapy of Cancer.